OncoCyte announces evaluation of gene expression test

2022 04 18 13 42 3384 Dna Genome Gene Targeted 400

OncoCyte has reported promising results in the Journal of Translational Medicine for its DetermaIO gene expression test in patients with metastatic bladder cancer.

In a clinical trial, 429 patients diagnosed with metastatic urothelial cancer were treated with atezolizumab (Tecentriq, Genentech), an immune checkpoint inhibitor.

DetermaIO identified 40% of the 348 patients available for DetermaIO biomarker analysis as likely responders.

These patients had a median survival of 15.6 months, compared to 8.8 months without biomarker stratification, according to the study. At two years, 41.5% of DetermaIO-positive patients were alive versus 28.6% of the population as a whole.

"This approach demonstrated that DetermaIO outperformed previously published gene expression signatures and additional conventional biomarkers, which supports its superior clinical utility in bladder cancer and keeps us on track for a [Centers for Medicare and Medicaid Services (CMS)] submission this fall," Dr. Doug Ross, chief science officer at OncoCyte, said in a statement.

Page 1 of 15
Next Page